MBX Biosciences, Inc. MBX
54.06 USD +2.71 (+5.28%)
At closeNov 9, 2026, 4:00 PM EST
54.06 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
51.96 Day range 54.86
23.07 52-week range 72.64
- YTD
- +71.40%
- 1 year
- +111.42%
News
benzinga.com Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84 Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $84.
benzinga.com Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150 Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $88 to $150.
benzinga.com Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
benzinga.com MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating Once-Weekly Canvuparatide For Treatment Of Chronic Hypoparathyroidism Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durableone-year clinical benefitGlobal registrational trial to enroll approximately 160 adults with HP to support
benzinga.com JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.
benzinga.com Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88 Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.- benzinga.com MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) Estimate MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.63) by 23.81 percent. This is a 34.48 percent decrease over losses of…
benzinga.com Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91 Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $57 to $91.
benzinga.com ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-market session. The company's market cap stands at $1.7 million. Medicus Pharma (NASDAQ:MDCX) stock rose…- benzinga.com MBX Biosciences Appoints Steve Hoerter As Chairman And CEO, Succeeding Kent Hawryluk, With John Smither Named Interim CFO, Effective Immediately MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of…
benzinga.com MBX Biosciences Highlights Sustained Calcium Control In Rare Disease MBX Biosciences reported one-year canvuparatide data showing sustained calcium control and progress toward a Phase 3 trial.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results. Other stocks declining in pre-market trading.- benzinga.com MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoing OLE Study Of Once-Weekly Canvuparatide In Adult Patients With Chronic Hypoparathyroidism Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trialResults consistent with restoration of systemic PTH activity through serum calcium
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70 Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises the price target from $66 to $70.- benzinga.com Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86 Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:MBX) with a Market Outperform and raises the price target from $76 to $86.
benzinga.com Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $70 Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $50 to $70.- benzinga.com MBX Biosciences Announces Multiple Updates On Obesity Portfolio; Preliminary Blinded Phase 1 Data For MBX 4291 Show Pharmacokinetic Profile Supporting Potential For Once-Monthly Dosing And Competitive Weight Loss In First MAD Cohort Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)MBX 4291 generally well…
- benzinga.com MBX Biosciences Q1 EPS $(0.51) Beats $(0.61) Estimate MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.61) by 16.39 percent. This is a 28.17 percent increase over losses of…
- benzinga.com MBX Biosciences Q4 EPS $(0.49) Beats $(0.68) Estimate MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.68) by 27.84 percent. This is a 4.26 percent decrease over losses of…
- benzinga.com Earnings Scheduled For February 12, 2026
- benzinga.com Barclays Initiates Coverage On MBX Biosciences with Overweight Rating, Announces Price Target of $66 Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweight rating and announces Price Target of $66.
- benzinga.com Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $88 Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $77 to $88.
- benzinga.com UBS Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $60 UBS analyst Michael Yee initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $60.
benzinga.com Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - benzinga.com Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $50 Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $45 to $50.
- benzinga.com Earnings Scheduled For December 18, 2025
- benzinga.com Goldman Sachs Initiates Coverage On MBX Biosciences with Sell Rating, Announces Price Target of $18 Goldman Sachs analyst Corinne Johnson initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Sell rating and announces Price Target of $18.
- benzinga.com Guggenheim Maintains Buy on MBX Biosciences, Lowers Price Target to $77 Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and lowers the price target from $84 to $77.
- benzinga.com MBX Biosciences Q3 EPS $(0.63) Beats $(0.70) Estimate MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.70) by 9.87 percent. This is a 77.34 percent increase over losses of…
benzinga.com This Twist Bioscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday 
benzinga.com Truist Securities Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $50 Truist Securities analyst Srikripa Devarakonda initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $50.
benzinga.com Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the…
benzinga.com Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.- benzinga.com Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $56 Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $38 to $56.
- benzinga.com Oppenheimer Maintains Outperform on MBX Biosciences, Raises Price Target to $80 Oppenheimer analyst Trevor Allred maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $38 to $80.
- benzinga.com Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $84 Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $44 to $84.
benzinga.com Stock Market Today: Dow Futures Rise, Nasdaq, S&P 500 Slip Amid Mixed Trade—Kenvue, Micron Tech, Nvidia In Focus (UPDATED) U.S. stock futures were fluctuating on Tuesday following Monday's record advances. Futures of major benchmark indices were mixed.
benzinga.com AutoZone, Micron Technology And 3 Stocks To Watch Heading Into Tuesday U.S. stock futures down, focus on AutoZone, Firefly Aerospace earnings, AAR Corp. results, MBX Biosciences public offering.- benzinga.com MBX Biosciences Announces Proposed Underwritten Public Offering Of 10M Shares Of Its Common Stock CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Gold Gains Over 1%; Quantum Computing Shares Plunge 
benzinga.com PROS Holdings, MBX Biosciences, Metsera, Anywhere Real Estate And Other Big Stocks Moving Higher On Monday 
benzinga.com Dow Falls Over 100 Points; Chicago Fed National Activity Index Rises In August 
benzinga.com MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study MBX Biosciences reported Phase 2 trial success for once-weekly canvuparatide, with strong efficacy, safety profile, and plans for Phase 3 in 2026.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Market-Moving News for September 22nd MBX: 46% | MBX Biosciences shares are trading higher after the company announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for…
- benzinga.com MBX Biosciences Announced Once-weekly Canvuparatide Achieved The Primary Endpoint With Statistical Significance In Its Phase 2 Avail Trial Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE)Positive findings in bone…